
Research
Study shows two CAR T cell therapies cost-effective as second- and third-line treatments for adults with diffuse large B-cell lymphoma
Findings add new evidence, perspective to support research on CAR T cell therapy cost-effectiveness
Research
Health & Wellness
Patient Care
Community
Patient Care
Patient Care
Health & Wellness
Community
Patient Care
Patient Care